Welcome to the NObreath FeNO Monitor Website
What is FeNO?
The production of nitric oxide is often found to be higher in inflammatory conditions such as asthma and therefore FeNO monitoring can be used for the detection and management of such conditions2, but also to differentiate between COPD, ACOS other and interstitial lung diseases that are not assessed by other means, such as lung function3.
Airway inflammation is a central process in asthma and other lung diseases1. Being able to detect eosinophilic airway inflammation and monitor a patient’s response to treatment is regarded as a gold standard in the management of respiratory diseases.
Nitric oxide measurement is not intended as a stand-alone method for diagnosis and should be used in conjunction with other evaluation methods and tests4.
Using FeNO measurements to evaluate airway inflammation in asthma represents a significant advance in respiratory medicine5, but until now this has been an expensive test to deliver in everyday practice.
● Non-invasive, quick and easy to perform5
● Shows patient’s response to treatment, enabling the correct prescription of medication and safer/monitored adjustments
● Shows patient compliance
● Aids in identifying patients who do/do not require on-going treatment6
● Shown to be superior to the majority of conventional tests of lung function, such as peak flow recording and spirometry5
● Aids in differentiating between allergic (eosinophillic) and non-allergic asthma7.
FeNO in Asthma
A majority of asthma patient’s airway inflammation is allergen-driven Th2 response12. There is significant evidence from external literature suggesting FeNO (Nitric oxide) is a key biomarker tool for inflammation of the respiratory tract12. Increased levels of FeNO in asthma are thought to come from inducible NOS2 expressed in the inflamed airways12. NObreath offers an alternative aid to diagnose asthma, which is non-invasive, and significantly more cost effective than current gold standard methods for aiding to diagnose airway eosinophilic inflammation, further aiding in the diagnosis of asthma. As a result of substantial amounts of literature supporting FeNO measurements as an effective biomarker for asthma and other airway inflammation, FeNO breath testing is now recommended in NICE guidelines as an aid to diagnose allergic asthma13. Literature also suggests the ability for FeNO measurement to be used as good management tool for asthma14, assessing the effectiveness of treatments for patients, optimising asthma treatments.
International FeNO use
NObreath – what is it?
Full-colour touchscreen with easy-to-use
interfacing and onscreen motivational
Adult and Child Profiles
Adult & child patient profiles for best
sampling times and quick result referrals
Easily serviceable components,
saving time and money
The NObreath has over 10 years of clinical
use featuring in many studies worldwide
An ergonomic design, fully portable and
incorporated with SteriTouch® technology for
optimum infection control
NObreath dock for safe and convenient
storage, charging and synchronisation
Subject to correct use, maintenance and service.
Sensor operating life
Rechargeable Li-on battery via USB
*±5ppb of measured value ≤50ppb or ±10% of measured value >50ppb
**Subject to maintenance & servicing.
The NObreath mouthpiece is single-patient use and has an
integrated infection control filter which removes and traps
>99% of airborne bacteria and >96% of viruses 8.
Free from alcohol to ensure continued
performance of your monitor.
Pack of 50 wipes.
Here’s what’s included:
• USB connection to the NObreath
• Create, store, and manage Patient Profiles
• Adult and child breath tests with screen mirroring
• View results in graph format
• Create reports in PDF format
• Embedded NObreath how-to videos
• FeNOchart™ automatically updates on start-up
• GDPR compliant with user logins and accounts
• A firmware update tool for the NObreath
Last but not least, there are more exciting features to come, including but not limited to:
• Download readings from your NObreath and save them directly to the patient profile
• Ambient NO tests with screen mirroring
• Multiple languages for the software
Medical Advisory Board
Professor at Universidade Brasil, Supervisor of MSc and PhD Program at UNIFESP and Director of IBEPIPE, Rodolfo de Paula Vieira has a PHD in Pathology – specifically the Immunopathology of the lungs – and 3 post-doctoral accreditations from the Sao Paulo, School of Medicine in Brazil, the Department of Pneumology at the University Hospital Freiburg in Germany and a post-doctoral fellowship awarded by European Respiratory Society and Marie Currie Foundation and European Union. Having published more than 100 internationally peer-reviewed scientific articles, Professor Vieira’s main pre and clinical studies evolve around immune response and the effects of physical exercise on pulmonary rehabilitation.
Professor and honorary consultant specialising in campus to clinic research, Dr Dominick Shaw’s main research interest is in severe asthma. He is the Nottingham lead in the largest asthma research consortium to date, the international £20M UBIOPRED EU IMI severe asthma project which is defining a phenotypic handprint in chronic severe asthma. Dr Shaw is also the lead for the commissioned severe asthma service, a past member of the British Thoracic Society’s asthma advisory group, and he also contributed to past BTS/SIGN national asthma guidelines. Currently, Dr Shaw sits on the Asthma and NIHR RfpB UK research boards.
John Dickinson is a BASES (The British Association of Sport and Exercise Sciences) accredited Sport and Exercise Physiologist and his main area of research focuses on respiratory problems in athletes. He has over 10 years’ experience of investigating issues such as asthma and dysfunctional breathing in athletes. John has published extensively in the area of exercise induced asthma and has given key note presentations internationally on the subject. Since 2008, he has been a UK Sport Advisor for asthma diagnosis in elite athletes and has worked alongside many professional football and rugby clubs as well as professional and Olympic athletes.
What we do:
- Work hard to design and manufacture the most up to date, high quality, innovative products for use by worldwide health professionals.
- Re-invest our profit into future research and development to keep our products up to life saving standards.
- Strive to produce high quality consumables at the lowest possible prices.
- Are committed to provide a very high level of quality customer service that takes account of the changing needs and expectations of our customers.
- Work to continuously improve the quality in all that we do.
The NObreath FeNO monitor is a product from Bedfont Scientific Ltd.
Incorporated in England and Wales under registered number: 1289798
1. Shelhamer JH, Levine SJ, Wu T, Jacoby DB, Kaliner MA, Rennard SI. NIH conference: airway inflammation. Ann Intern Med 1995;123:288-304.
2. Saito J, Gibeon D, Macedo P, Menzies-Gow A, Bhavsar P, Chung K. Domiciliary diurnal variation of exhaled nitric oxide fraction for asthma control. 2017.
3. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005; American Journal of Respiratory and Critical Care Medicine; vol. 171: 912-930;2005
4. Correlation of Exhaled Nitric Oxide, Spirometry and Asthma Symptoms: Journal of Asthma: Vol 42, No 10 [Internet]. Tandfonline.com. 2017 [cited 15 March 2017]. Available from: http://www.tandfonline.com/doi/abs/10.1080/02770900500371344
5. Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris MacLachlan, Gabrielle Monti Sheehan, Pamela Jackson and D. Robin Taylor. Diagnosing Asthma: Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests. Am J Respir Crit Care Med Vol 169. pp 473-478, 2004.
6. D R Taylor, MW Pinenburg, A D Smith and J C D Jongste. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006;61:817-827.
7. Coumou HBel E. Improving the diagnosis of eosinophilic asthma [Internet]. Taylor and Francis online. 2017 [cited 15 March 2017]. Available from: http://www.tandfonline.com/doi/full/10.1080/17476348.2017.1236688
8. Public Health England. An Evaluation of Filtration Efficiencies Against Bacterial and Viral Aerosol Challenges Report No. 18/040. London: Public Health England; 2019.
9. Asthma facts and statistics | Asthma UK [Internet]. Asthma UK. 2019 [cited 2 December 2019]. Available from: https://www.asthma.org.uk/about/media/facts-and-statistics/
10. Kudo M, Ishigatsubo Y, Aoki I. Pathology of asthma. Frontiers in Microbiology. 2013;.
11. PIZZICHINI E, PIZZICHINI M, EFTHIMIADIS A, DOLOVICH J, HARGREAVE F. Measuring airway inflammation in asthma: Eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood. Journal of Allergy and Clinical Immunology. 1997;99(4):539-544.
12. Keller A, Rodriguez D, Russo M. Nitric oxide paradox in asthma. Memórias do Instituto Oswaldo Cruz. 2005;100(suppl 1):19-23.
13. Asthma – NICE CKS [Internet]. Cks.nice.org.uk. 2019 [cited 2 December 2019]. Available from: <a href=”https://cks.nice.org.uk/asthma#!diagnosisSub” title=”click for more information”>https://cks.nice.org.uk/asthma#!diagnosisSub</a>
14.Ricciardolo F, Sorbello V, Ciprandi G. FeNO as biomarker for asthma phenotyping and management. Allergy and Asthma Proceedings. 2015;36(1):88-88.